MAXIMUS Shows Strong Revenue in Fiscal 4Q15
MAXIMUS’ price movement
MAXIMUS (MMS) has a market capitalization of $3.5 billion. MAXIMUS’s YTD (year-to-date) price movement was a mix of rises and falls in 2015.
After its fiscal 4Q15 earnings report, MMS fell by 21.9% to close at $53.61 per share as of November 12, 2015. The stock’s price movements on a weekly, monthly, and YTD basis are -21.9%, -15.9%, and -2.0%, respectively.
Technically, MMS has broken the support of, and is trading below, all of its moving averages. Currently, it’s trading at -20.5% below its 20-day moving average, -16.3% below its 50-day moving average, and -16.1% below its 200-day moving average.
The Guggenheim S&P MidCap 400 Pure Growth ETF (RFG) invests 1.5% of its holdings in MAXIMUS. The ETF tracks a factor-weighted index of the S&P 400 companies exhibiting the strongest growth factors. The YTD price movement of RFG is 6.7% as of November 11, 2015.
MAXIMUS ‘s competitors and their market capitalizations are as follows:
- Accenture (ACN) — $68.2 billion
- Xerox (XRX) — $10.3 billion
- Broadridge Financial Solutions (BR) — $6.7 billion
- ExlService Holdings (EXLS) — $1.5 billion
Performance of MAXIMUS in fiscal 4Q15 and fiscal 2015
MAXIMUS reported revenue of $578.7 million in fiscal 4Q15, a rise of 32.9% when compared to its revenue of $435.4 million in fiscal 4Q14.
Revenues from its Health Services, US Federal Services, and Human Services segments rose by 28.6%, 70.3%, and 12.1%, respectively, in 4Q15 compared to the segements’ revenues in 4Q14. Revenues from its Health Services and Human Services segments fell by 0.77% and 3.4%, respectively, and revenue from US Federal Services segment rose by 9.4%, respectively, on a quarterly basis.
The company’s YTD signed contracts rose to $3.4 billion in 4Q15, a rise of 17.2% on a quarterly basis. Its new contracts pending (awarded but unsigned) fell by 41.7% in 4Q15 on a quarterly basis.
The company’s cost of revenue as a percentage of revenue rose by 5.4% in 4Q15 compared to 4Q14. Its net income fell to $35.4 million in 4Q15 compared to its net income of $36.2 million in 4Q14. Its diluted EPS (earnings per share) remained the same same, at $0.53 per share in 4Q15 and 4Q14.
MAXIMUS authorized the repurchase of up to $200 million of its stock. It also declared a quarterly cash dividend of $0.045 per share on its common stock.
In fiscal 2015, the company’s revenue rose to $2,099.8 million, a rise of 23.4% on a yearly basis. Revenue from its Health Services, US Federal Services, and Human Services segments rose by 22.3%, 47.0%, and 7.9%, respectively, in fiscal 2015 on a yearly basis.
MAXIMUS’s fiscal 2015 operating income rose by 15.3%. Its net income and EPS rose to $157.8 million and $2.35 compared to its net income and EPS of $145.4 million and $2.11 in fiscal 2014. Backlog orders were at $4.6 billion as of September 30, 2015.
Meanwhile, the company’s cash and cash equivalents fell by 52.8% and its accounts receivable rose by 47.5% in fiscal 2015 on a yearly basis. Its current ratio fell to 1.62 and its debt-to-equity ratio rose to 1.07 compared to its fiscal 2014 current and debt-to-equity ratios of 2.00 and 0.61, respectively.
The company has projected the following numbers for fiscal 2016:
- Revenue: in the range of $2.4–$2.5 billion
- Diluted EPS: $2.40–$2.70 per share
MAXIMUS provides business process management and technology solutions that improve outcomes and increase the productivity, accuracy, accountability, and efficiency of government-sponsored programs.
Browse this series on Market Realist: